Quarterly ResultMay 5, 2026, 03:27 PM
ACRO BIOMEDICAL Q1 Net Loss $(43,774); Going Concern Doubts
AI Summary
ACRO BIOMEDICAL CO., LTD. reported a net loss of $(43,774) for the three months ended March 31, 2026, a significant increase from $(10,301) in the prior year period. The company continues to generate no revenue, has minimal cash, and faces substantial doubt about its ability to continue as a going concern. Operations are primarily funded by advances from a minority stockholder, and disclosure controls were found to be ineffective.
Key Highlights
- Net loss for Q1 2026 was $(43,774), significantly higher than $(10,301) in Q1 2025.
- Company reported no revenue for Q1 2026, continuing a trend since December 31, 2022.
- Operating expenses surged to $60,271 in Q1 2026 from $8,934 in Q1 2025.
- Cash balance stood at $3,873 as of March 31, 2026, down from $4,098 at Dec 31, 2025.
- Total assets decreased to $3,873 at March 31, 2026 from $14,098 at Dec 31, 2025.
- Stockholders' deficit worsened to $(427,235) at March 31, 2026.
- Management expressed substantial doubt about the company's ability to continue as a going concern.
- Disclosure controls were deemed ineffective due to lack of segregation of duties and qualified personnel.